



iBRA – NET NEWSLETTER



visit ibra-net.com for more information

MEET THE TEAM



Mr Baek Kim is a Consultant Oncoplastic Breast Surgeon at the Leeds Breast Unit. He trained in the Yorkshire Deanery and completed the National Oncoplastic TIG fellowship in Newcastle. He was awarded an MD degree at the University of Leeds for a translational research project investigating potential biomarkers in breast cancer patients treated with neoadjuvant systemic therapy. He is a member of the ABS academic and research committee and currently leading on the delivery of the MARECA study. He is co-supervising MD and PhD students at the University of Leeds who are carrying out

translational breast cancer research projects. He held previous role as a Mammary Fold academic subcommittee member and has been on the study steering committee for national research collaborative studies including the B-MaP-C and TeaM study. He is the local PI in Leeds for the POETIC-A, RESTORE-C19, and PROM-Q studies.

MARECA STUDY

Study Lead: Mr Baek Kim

Trial Manager & Co-ordinator: Sue Hartup & Claire Young

The MARECA Study (National Study of Management of Breast Cancer Locoregional Recurrence and Oncological Outcome) opened to patient recruitment in December 2021. The trial is currently open in 40 UK NHS Trusts and recruited 414 patients. A further 10 sites are currently in the set up phase. The study aims to recruit 500 patients and will remain open to patient recruitment until December 2023.

ASPIRE STUDY

Study Leads: Ms Jennifer Hu and Mr Rajiv Dave

Clinical Trials administrator: Alice Cui

If your unit would like to be involved please contact: abs.aspire.project@gmail.com

A multicentre platform study to evaluate the safety (number of breast cancers diagnosed in 12 months following assessment), patient satisfaction and cost of novel breast pain pathways compared to standard one stop clinic assessment. To date there has been successful onboarding of 16 units with two more scheduled. St Barts have recruited the first 10 patients.

[View the ASPIRE Launch Webinar here](#)




The ANTHEM study

Study Lead: Ms Shelly Potter

Study Manager: Charlotte Davies

A study to determine the feasibility of undertaking a large scale study comparing clinical and patient reported outcomes of oncoplastic breast conservation as an alternative to mastectomy +/- immediate breast reconstruction

The study has met its recruitment target! 387 women have been recruited from 31 UK centres. Three month clinical and patient reported outcome analysis has begun



Top 6 recruiting sites

Newcastle RVI	54
Ipswich Hospital	37
Royal Liverpool Hospital	36
Worthing Hospital	35
Aberdeen Royal	34
Tayside	32

LOCALISATION STUDIES


Study Leads: Mr Rajiv Dave and Mr James Harvey

Clinical Trials administrator: Suzy Krizak

For further information please contact us: localisationstudy@gmail.com

SCOUT Study (2021 – Active)


Aim: evaluate the outcomes of non-palpable breast lesion localisation-guided surgery and also establish the efficacy of axillary node marking using the Savi Scout® System. Our database currently holds 380 records from 62 users over 23 sites. We would like to thank our collaborators for their data so far and we will continue to collect data....



PINTUTION Study (2022-Active)

Aim: evaluate the outcomes of non-palpable breast lesion localisation-guided surgery and also establish the efficacy of axillary node marking using Sirius Pintuition® System. Our database currently holds 215 records from 30 users over 15 sites. We would like to thank our collaborators for their data so far and we will continue to collect data....


PINTUTION Data Analysis
Total: 215



[View the SIRIUS PINTUTION "Lessons Learned" webinar here](#)

HOLOGIC Study (2021-2022 Closed)

Aim: evaluate the outcomes of non-palpable breast lesion localisation-guided surgery using the LOCalizer™ Radiofrequency Identification (RFID) System. Our HOLOGIC Study database holds 1433 records from 73 users over 33 sites. We would like to thank our collaborators and we look forward to further data analysis and to publishing our paper very soon.



MAGSEED Study (2018 – 2020 Closed)

Aim: to compare safety and effectiveness of wire and magnetic seed guided localization techniques

35 participating units, 2300 patients

Lesion localization rate 99.8% Magseed vs. 99.1% wire. Equivalent complication rates, specimen weight and safety. Magseed is highly accurate and comparable with wire localisation when used in normal practice in a multicentre manner

[Rajiv V. Dave et al. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study, British Journal of Surgery](#)

INNOVATION GROUP

Chair: Mr Edward St John

Our mission is to identify, evaluate and translate great innovations into breast surgical practice for the benefit of our patients. We encourage clinicians and industry to submit your innovations at <https://www.ibra-net.com/innovations>